The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
CFTR modulator theratyping: Current status, gaps and future directions
Open accessAbstract
BACKGROUND: New drugs that improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein with discreet disease-causing variants have been successfully developed for cystic fibrosis (CF) patients. Preclinical model systems have played a critical role in this process, and have the potential to inform researchers and CF healthcare providers regarding the nature of defects in rare CFTR variants, and to potentially support use of modulator therapies in new populations. METHODS: The Cystic Fibrosis Foundation (CFF) assembled a workshop of international experts to discuss the use of preclinical model systems to examine the nature of CF-causing variants in CFTR and the role of in vitro CFTR modulator testing to inform in vivo modulator use. The theme of the workshop was centered on CFTR theratyping, a term that encompasses the use of CFTR modulators to define defects in CFTR in vitro, with application to both common and rare CFTR variants. RESULTS: Several preclinical model systems were identified in various stages of maturity, ranging from the expression of CFTR variant cDNA in stable cell lines to examination of cells derived from CF patients, including the gastrointestinal tract, the respiratory tree, and the blood. Common themes included the ongoing need for standardization, validation, and defining the predictive capacity of data derived from model systems to estimate clinical outcomes from modulator-treated CF patients. CONCLUSIONS: CFTR modulator theratyping is a novel and rapidly evolving field that has the potential to identify rare CFTR variants that are responsive to approved drugs or drugs in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Self-citationOrganoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · Nephron · doi:10.1159/000433566 · Cited by 3,515
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Self-citationLumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Self-citationRescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999
Self-citationCystic fibrosis genetics: from molecular understanding to clinical application
Cutting, G. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 965
Self-citationEffect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M. P., Dunitz, J. M., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 807
Self-citationTezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., Ingenito, E. P., McKee, C., Lu, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709846 · Cited by 794
Dekkers, J. F., Berkers, G., Kruisselbrink, E., Vonk, A., de Jonge, H. R., Janssens, H. M., Bronsveld, I., van de Graaf, E. A., Nieuwenhuis, E. E. S., Houwen, R. H. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8278 · Cited by 548
Self-citationTezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709847 · Cited by 522
Self-citationDavies, J. C., Wainwright, C. E., Canny, G. J., Chilvers, M. A., Howenstine, M. S., Munck, A., Mainz, J. G., Rodriguez, S., Li, H., Yen, K., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201301-0153oc · Cited by 510
Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0703oc · Cited by 492
Self-citationMcCauley, K. B., Hawkins, F., Serra, M., Thomas, D. C., Jacob, A., & Kotton, D. N. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.03.001 · Cited by 432
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Yu, H., Burton, B., Huang, C.-J., Worley, J., Cao, D., Johnson, J. P., Urrutia, A., Joubran, J., Seepersaud, S., Sussky, K., et al. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.12.005 · Cited by 423
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G., & Higgins, M. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.09.005 · Cited by 394
Hisert, K. B., Heltshe, S. L., Pope, C., Jorth, P., Wu, X., Edwards, R. M., Radey, M., Accurso, F. J., Wolter, D. J., Cooke, G., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1954oc · Cited by 389
Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells
Mou, H., Vinarsky, V., Tata, P. R., Brazauskas, K., Choi, S. H., Crooke, A. K., Zhang, B., Solomon, G. M., Turner, B., Bihler, H., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.05.012 · Cited by 382
Self-citationKerem, E., Konstan, M. W., De Boeck, K., Accurso, F. J., Sermet-Gaudelus, I., Wilschanski, M., Elborn, J. S., Melotti, P., Bronsveld, I., Fajac, I., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70100-6 · Cited by 346
Self-citationIvacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation
Flume, P. A., Liou, T. G., Borowitz, D. S., Li, H., Yen, K., Ordoñez, C. L., & Geller, D. E. (2012) · Chest · doi:10.1378/chest.11-2672 · Cited by 338
Self-citationConditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens
Liu, X., Krawczyk, E., Suprynowicz, F. A., Palechor-Ceron, N., Yuan, H., Dakic, A., Simic, V., Zheng, Y.-L., Sripadhan, P., Chen, C., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2016.174 · Cited by 299
Ratjen, F., Hug, C., Marigowda, G., Tian, S., Huang, X., Stanojevic, S., Milla, C. E., Robinson, P. D., Waltz, D., Davies, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30215-1 · Cited by 294
Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells
Suprynowicz, F. A., Upadhyay, G., Krawczyk, E., Kramer, S. C., Hebert, J. D., Liu, X., Yuan, H., Cheluvaraju, C., Clapp, P. W., Boucher, R. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213241109 · Cited by 291
Human Nasal and Tracheo-Bronchial Respiratory Epithelial Cell Culture
Fulcher, M. L., & Randell, S. H. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-62703-125-7_8 · Cited by 284
Konstan, M. W., McKone, E. F., Moss, R. B., Marigowda, G., Tian, S., Waltz, D., Huang, X., Lubarsky, B., Rubin, J., Millar, S. J., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30427-1 · Cited by 259
Firth, A. L., Dargitz, C. T., Qualls, S. J., Menon, T., Wright, R., Singer, O., Gage, F. H., Khanna, A., & Verma, I. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403470111 · Cited by 252
Konishi, S., Gotoh, S., Tateishi, K., Yamamoto, Y., Korogi, Y., Nagasaki, T., Matsumoto, H., Muro, S., Hirai, T., Ito, I., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.11.010 · Cited by 246
Sawicki, G. S., McKone, E. F., Pasta, D. J., Millar, S. J., Wagener, J. S., Johnson, C. A., & Konstan, M. W. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0578oc · Cited by 236
Moss, R. B., Flume, P. A., Elborn, J. S., Cooke, J., Rowe, S. M., McColley, S. A., Rubenstein, R. C., & Higgins, M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00201-5 · Cited by 228
Self-citationDavies, J., Sheridan, H., Bell, N., Cunningham, S., Davis, S. D., Elborn, J. S., Milla, C. E., Starner, T. D., Weiner, D. J., Lee, P.-S., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70182-6 · Cited by 224
Milla, C. E., Ratjen, F., Marigowda, G., Liu, F., Waltz, D., & Rosenfeld, M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1754oc · Cited by 168
Pranke, I. M., Hatton, A., Simonin, J., Jais, J. P., Le Pimpec-Barthes, F., Carsin, A., Bonnette, P., Fayon, M., Stremler-Le Bel, N., Grenet, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07504-1 · Cited by 161
Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data
Accurso, F. J., Goor, F. V., Zha, J., Stone, A., Dong, Q., Ordoñez, C. L., Rowe, S. M., Clancy, J. P., Konstan, M. W., Hoch, H. E., et al. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.09.007 · Cited by 151
Self-citationPharmacological Rescue of Conditionally Reprogrammed Cystic Fibrosis Bronchial Epithelial Cells
Gentzsch, M., Boyles, S. E., Cheluvaraju, C., Chaudhry, I. G., Quinney, N. L., Cho, C., Dang, H., Liu, X., Schlegel, R., & Randell, S. H. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0276ma · Cited by 151
Self-citationDurmowicz, A. G., Lim, R., Rogers, H. L., Rosebraugh, C. J., & Chowdhury, B. A. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201708-668ps · Cited by 148
Self-citationGraeber, S. Y., Dopfer, C., Naehrlich, L., Gyulumyan, L., Scheuermann, H., Hirtz, S., Wege, S., Mairbäurl, H., Dorda, M., Hyde, R., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-1983oc · Cited by 146
Boj, S. F., Vonk, A. M., Statia, M., Su, J., Dekkers, J. F., Vries, R., Beekman, J. M., & Clevers, H. C. (2017) · Journal of Visualized Experiments · doi:10.3791/55159 · Cited by 138
Self-citationNeuberger, T. J., Burton, B., Clark, H., & Goor, F. V. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-117-8_4 · Cited by 137
Influence of cell background on pharmacological rescue of mutant CFTR
Pedemonte, N., Tomati, V., Sondo, E., & Galietta, L. J. V. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00404.2009 · Cited by 136
Epithelial Chloride Transport by CFTR Requires TMEM16A
Benedetto, R. D., Ousingsawat, J., Wanitchakool, P., Zhang, Y., Holtzman, M. J., Amaral, M. D., Rock, J. R., Schreiber, R., & Kunzelmann, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-10910-0 · Cited by 129
Self-citationAirway Progenitor Clone Formation Is Enhanced by Y-27632–Dependent Changes in the Transcriptome
Reynolds, S. D., Rios, C. L., Wesolowska‐Andersen, A., Zhuang, Y., Pinter, M., Happoldt, C., Hill, C. L., Lallier, S. W., Cosgrove, G. P., Solomon, G. M., et al. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0274ma · Cited by 107
Self-citationLumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
Rowe, S. M., McColley, S. A., Rietschel, E., Li, X., Bell, S. C., Konstan, M. W., Marigowda, G., Waltz, D., & Boyle, M. P. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201609-689oc · Cited by 92
Self-citationRonan, N. J., Einarsson, G. G., Twomey, ., Mooney, D., Mullane, D., NíChróinín, M., O'Callaghan, G. P., Shanahan, F., Murphy, D. M., O’Connor, O. J., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.10.005 · Cited by 90
Fidler, M. C., Beusmans, J., Panorchan, P., & Goor, F. V. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.10.002 · Cited by 85
Lee, M., Roos, P., Sharma, N., Atalar, M., Evans, T. A., Pellicore, M. J., Davis-Marcisak, E. F., Lam, A.-T. N., Stanley, S. E., Khalil, S. E., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.04.001 · Cited by 79
Self-citationDonaldson, S. H., Solomon, G. M., Zeitlin, P. L., Flume, P. A., Casey, A. M. H., McCoy, K., Zemanick, E. T., Mandagere, A., Troha, J. M., Shoemaker, S. A., et al. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.01.009 · Cited by 77
Self-citationhPSC-derived lung and intestinal organoids as models of human fetal tissue
Aurora, M., & Spence, J. R. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.06.006 · Cited by 76
Biomarkers for cystic fibrosis drug development
Muhlebach, M. S., Clancy, J., Heltshe, S. L., Ziady, A. G., Kelley, T., Accurso, F. J., Pilewski, J. M., Mayer-Hamblett, N., Joseloff, E., & Sagel, S. D. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.10.009 · Cited by 71
Self-citationMcGarry, M. E., Illek, B., Ly, N. P., Zlock, L. T., Olshansky, S., Moreno, C., Finkbeiner, W. E., & Nielson, D. W. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23659 · Cited by 68
Self-citationOptimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids
Dekkers, J. F., Gondra, R. A. G., Kruisselbrink, E., Vonk, A. M., Janssens, H. M., Groot, K. M. D. W., van der Ent, C. K., & Beekman, J. M. (2016) · European Respiratory Journal · doi:10.1183/13993003.01192-2015 · Cited by 67
Self-citationGraeber, S. Y., Hug, M. J., Sommerburg, O., Hirtz, S., Hentschel, J., Heinzmann, A., Dopfer, C., Schulz, A., Mainz, J. G., Tümmler, B., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1271le · Cited by 65
Goss, C. H., Sykes, J. R., Stanojevic, S., Marshall, B. C., Petren, K., Ostrenga, J., Fink, A. K., Elbert, A., Quon, B. S., & Stephenson, A. L. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1541oc · Cited by 63
Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor
Stalvey, M. S., Pace, J., Niknian, M., Higgins, M. N., Tarn, V., Davis, J. M., Heltshe, S. L., & Rowe, S. M. (2017) · PEDIATRICS · doi:10.1542/peds.2016-2522 · Cited by 62
Self-citationDetection of CFTR function and modulation in primary human nasal cell spheroids
Brewington, J. J., Filbrandt, E. T., LaRosa, F. J., Ostmann, A. J., Strecker, L. M., Szczesniak, R. D., & Clancy, J. P. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.06.010 · Cited by 57
Self-citationRowe, S. M., Liu, B., Hill, A. E., Hathorne, H. Y., Cohen, M., Beamer, J. R., Accurso, F. J., Dong, Q., Ordoñez, C. L., Stone, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066955 · Cited by 51
Self-citationCystic Fibrosis and Its Management Through Established and Emerging Therapies
Spielberg, D. R., & Clancy, J. P. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-050024 · Cited by 51
Self-citationNasospheroids permit measurements of CFTR-dependent fluid transport
Guimbellot, J. S., Leach, J. M., Chaudhry, I. G., Quinney, N. L., Boyles, S. E., Chua, M., Aban, I., Jaspers, I., & Gentzsch, M. (2017) · JCI Insight · doi:10.1172/jci.insight.95734 · Cited by 45
Self-citationFarinha, C. M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., & Amaral, M. D. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.152 · Cited by 44
Self-citationA bioassay using intestinal organoids to measure CFTR modulators in human plasma
Dekkers, R., Vijftigschild, L. A. W., Vonk, A. M., Kruisselbrink, E., Groot, K. M. D. W., Janssens, H. M., van der Ent, C. K., & Beekman, J. M. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.10.007 · Cited by 44
Self-citationPersonalized medicine for cystic fibrosis: Establishing human model systems
Mou, H., Brazauskas, K., & Rajagopal, J. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23233 · Cited by 42
Gottschalk, L., Vecchio-Pagán, B., Sharma, N., Han, S. T., Franca, A., Wohler, E., Batista, D., Goff, L. A., & Cutting, G. R. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.11.010 · Cited by 42
Self-citationAn update on new and emerging therapies for cystic fibrosis
Hudock, K. M., & Clancy, J. P. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1418324 · Cited by 30
Self-citationMeasurement of Ion Transport Function in Rectal Biopsies
Hug, M. J., Derichs, N., Bronsveld, I., & Clancy, J. P. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-117-8_7 · Cited by 24
Self-citationGuanylate cyclase 2C agonism corrects CFTR mutants
Arora, K., Huang, Y., Mun, K., Yarlagadda, S., Sundaram, N., Kessler, M. M., Hannig, G., Kurtz, C. B., Silos‐Santiago, I., Helmrath, M. A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93686 · Cited by 20
Self-citation
Cited by
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Self-citationScotet, V., L’Hostis, C., & Férec, C. (2020) · Genes · doi:10.3390/genes11060589 · Cited by 317
Ong, T., & Ramsey, B. W. (2023) · JAMA · doi:10.1001/jama.2023.8120 · Cited by 315
Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis
Ramalho, A. S., Fürstová, E., Vonk, A. M., Ferrante, M., Verfaillie, C., Dupont, L., Boon, M., Proesmans, M., Beekman, J. M., Sarouk, I., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02426-2019 · Cited by 121
Self-citationThe impact of CFTR modulator therapies on CF airway microbiology
Rogers, G. B., Taylor, S. L., Hoffman, L. R., & Burr, L. D. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.008 · Cited by 52
Metadata
- Authors
- Clancy, J. P., Cotton, C. U., Donaldson, S. H., Solomon, G. M., VanDevanter, D. R., Boyle, M. P., Gentzsch, M., Nick, J. A., Illek, B., Wallenburg, J. C., Sorscher, E. J., Amaral, M. D., Beekman, J. M., Naren, A. P., Bridges, R. J., Thomas, P. J., Cutting, G., Rowe, S., Durmowicz, A. G., Mense, M., Boeck, K. D., Skach, W., Penland, C., Joseloff, E., Bihler, H., Mahoney, J., Borowitz, D., & Tuggle, K. L.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 18
- Issue
- 1
- Pages
- 22-34
- ISSN
- 1569-1993 (ISSN-L)
- OpenAlex
- W2808871427
- Cited by
- 291
- References
- 68
- FWCI
- 19.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.